publication date: Feb. 3, 2014


CCL37-01e.html

Liver Cancer
Post-Hoc Analysis of ThermoDox Suggests OS Improvement

A post-hoc analysis of results from the phase III HEAT Study of ThermoDox, a heat-activated liposomal encapsulation of doxorubicin in combination with radio frequency ablation, suggests the agent may significantly improve overall survival in primary liver cancer patients that receive RFA treatment for 45 minutes or more.

This analysis followed the announcement on January 31, 2013, that the HEAT Study did not meet its primary endpoint of progression-free survival.

As provided for in the HEAT Study’s Special Protocol Assessment agreement with FDA, the drug’s sponsor, Celsion Corporation, continues to follow patients for overall survival. Data from four quarterly reviews of overall survival have been evaluated since the announcement of top-line PFS data.

These findings apply to patients with single HCC lesions, 64.4 percent of the HEAT Study population, from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a subgroup of 285 patients, or 41 percent of the patients in the HEAT Study.

In the patient subgroup treated in the ThermoDox arm whose RFA procedure lasted longer than 45 minutes (n=285, or 63 percent of single lesion patients), clinical results indicate a 55 percent improvement in overall survival (HR=0.64; 95% CI: 0.41-1.00; p=0.0495). Median overall survival for this subgroup has not yet been reached.

In contrast, the patient subgroup treated with ThermoDox whose RFA procedure lasted less than 45 minutes in duration (n=167, or 37 percent of single lesion patients) indicated a Hazard Ratio of 1.12 (95% CI 0.68 – 1.86) and a P-value = 0.66. Median overall survival for this subgroup has not … Continue reading CCL Jan – Liver Cancer

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.